February 2, 2018
Showing 5011 - 5020 of 8169 results
April 28, 2017
New Taxonomy of Health Would Improve Outcomes, Reimbursement
April 7, 2014
New Toolkit to Measure Quality of Person-Centered Care: Development and Pilot Evaluation With Nursing Home Communities
Increasingly, nursing home (NH) providers are adopting a person-centered care (PCC) philosophy; yet, they currently lack methods to measure their progress toward this goal. Few PCC tools meet criteria for ease of use and feasibility in NHs. The purpose of this article is to report on the development of the...September 28, 2015
New Treatment Target for Hypothyroid in Elderly Patients
May 5, 2025
New Vice President Wants to Make Sure Your Voices Are Heard
Diane Sanders-Cepeda, DO, CMD, PALTmed’s new vice president, wants every member to know their voice matters. “The knowledge and insights our members have around delivering quality, improving care, and building community define our organization,” she says. “And this is what motivates me, this responsibility...February 26, 2016
New VTE Guidelines Favor NOACs Over Warfarin
March 2, 2015
New, Limited Rx Coming for Orthostatic Hypotension
Newly Approved Treatment in Alzheimer’s Disease
Join us for a live webinar June 24 at 12:00 PM EST and be among the first to learn about a newly approved treatment for Alzheimer’s disease! In collaboration with Alpha Cognition, this edition will educate on the differentiation of the newly approved treatment based on its underlying technology and mechanism of action, as well as review the treatment’s efficacy and safety established from clinical trials and real-world evidence. The speakers, including Michael McFadden, Chief Executive Officer at Alpha Cognition, will enable participants to explore unmet needs in the treatment of Alzheimer’s Disease and learn about a new treatment. Register now.
US-ZUNV-00069 V1
Newly Approved Treatment in Alzheimer’s Disease
Join us for a live webinar July 29 at 12:00 PM EST and be among the first to learn about a newly approved treatment for Alzheimer’s disease! In collaboration with Alpha Cognition, this edition will educate on the differentiation of the newly approved treatment based on its underlying technology and mechanism of action, as well as review the treatment’s efficacy and safety established from clinical trials and real-world evidence. The speakers, including Michael McFadden, Chief Executive Officer at Alpha Cognition, will enable participants to explore unmet needs in the treatment of Alzheimer’s Disease and learn about a new treatment. Register now.
US-ZUNV-00069 V1
July 31, 2015